|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.
|
12094250 |
2002 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, we found that the G6 CRI also is expressed frequently by neoplastic CD5 (Leu1) B cells from patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
|
2503826 |
1989 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The leukemic cells from 95% of patients with B cell chronic lymphocytic leukemia (CLL) coexpress B cell differentiation antigens and the pan-T lymphocyte surface antigen CD5 (Leu 1).
|
1689356 |
1990 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The nondeleted allele of the CAR and EST70/Leu1 genes was expressed in B-CLL specimens, including those with monoallelic loss, whereas no expression of 1B4/Leu2 was detectable in B-CLL, regardless of the 13q14 status.
|
11264177 |
2001 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Flow cytometric analysis of forward- and right-angle light scatters demonstrated the presence of two populations of cells, one lymphoid, bearing predominantly lambda light chain surface immunoglobulin and showing phenotypic characteristics of B cell chronic lymphocytic leukemia (HLA-DR-positive, BL-1-positive, BL-2-positive, BL-7-positive, Leu-1-positive, Leu-10-positive, BL-5-negative, BL-6-negative, and OKM1-negative), and another granulocytic population expressing phenotypic features compatible with myeloid lineage (HLA-DR-negative, Leu-1-negative, BL-1-negative, BL-2-negative, BL-7-negative, Leu-10-negative, BL-5-positive, BL-6-negative, OKM1-positive, and surface immunoglobulin-negative).
|
3456199 |
1986 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Malignant CD5 B cells obtained from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were analyzed for immunoglobulin variable gene usage, CD5 gene expression and autoantibody production.
|
1721931 |
1991 |
|
Chronic Lymphocytic Leukemia
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We studied the presence of MSI in the CD5 promoter in 134 cases of B-cell chronic lymphocytic leukemia (B-CLL) and 47 of mantle cell lymphoma (MCL) by comparing the pattern of microsatellite repeats on autologous germline and tumor DNA samples.
|
15981803 |
2005 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
We studied the presence of MSI in the CD5 promoter in 134 cases of B-cell chronic lymphocytic leukemia (B-CLL) and 47 of mantle cell lymphoma (MCL) by comparing the pattern of microsatellite repeats on autologous germline and tumor DNA samples.
|
15981803 |
2005 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
Biomarker
|
disease |
BEFREE |
Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.
|
12094250 |
2002 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
Biomarker
|
disease |
BEFREE |
Flow cytometric analysis of forward- and right-angle light scatters demonstrated the presence of two populations of cells, one lymphoid, bearing predominantly lambda light chain surface immunoglobulin and showing phenotypic characteristics of B cell chronic lymphocytic leukemia (HLA-DR-positive, BL-1-positive, BL-2-positive, BL-7-positive, Leu-1-positive, Leu-10-positive, BL-5-negative, BL-6-negative, and OKM1-negative), and another granulocytic population expressing phenotypic features compatible with myeloid lineage (HLA-DR-negative, Leu-1-negative, BL-1-negative, BL-2-negative, BL-7-negative, Leu-10-negative, BL-5-positive, BL-6-negative, OKM1-positive, and surface immunoglobulin-negative).
|
3456199 |
1986 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The nondeleted allele of the CAR and EST70/Leu1 genes was expressed in B-CLL specimens, including those with monoallelic loss, whereas no expression of 1B4/Leu2 was detectable in B-CLL, regardless of the 13q14 status.
|
11264177 |
2001 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.050 |
Biomarker
|
disease |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The CD5 gene expression was in all cases identical to that of T-cell malignancies.
|
1690580 |
1990 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
This suggests that although MSI seems not to be involved in the pathogenesis of these 2 lymphoid malignant neoplasms, the polymorphic CD5 promoter is associated with increased susceptibility to these disorders.
|
15981803 |
2005 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
We determined that the transcription of the CD5 gene in T cell malignancies, CLL, SLL and a selected group of EBV transformed lines was identical.
|
1721931 |
1991 |
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Two adjacent genes, termed Leu1 and Leu2 (leukemia-associated gene 1 and 2), were mapped to the minimally deleted region, with several patients showing deletion borders within these genes.
|
9395242 |
1997 |
|
leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have recently identified a minimally deleted region encompassing parts of two adjacent genes, termed LEU1 and LEU2 (leukemia-associated genes 1 and 2), and several additional transcripts.
|
11161783 |
2000 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Because of these results and that no mutations were detected on the two genes in a previous study, we think that Leu1 and Leu2 can be excluded as tumor suppressor genes.
|
10516767 |
1999 |
|
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
We studied the presence of MSI in the CD5 promoter in 134 cases of B-cell chronic lymphocytic leukemia (B-CLL) and 47 of mantle cell lymphoma (MCL) by comparing the pattern of microsatellite repeats on autologous germline and tumor DNA samples.
|
15981803 |
2005 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.
|
9395242 |
1997 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
|
15981803 |
2005 |
|
Small Lymphocytic Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently, we found that the G6 CRI also is expressed frequently by neoplastic CD5 (Leu1) B cells from patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
|
2503826 |
1989 |
|
Small Lymphocytic Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Malignant CD5 B cells obtained from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were analyzed for immunoglobulin variable gene usage, CD5 gene expression and autoantibody production.
|
1721931 |
1991 |
|
Childhood Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Two adjacent genes, termed Leu1 and Leu2 (leukemia-associated gene 1 and 2), were mapped to the minimally deleted region, with several patients showing deletion borders within these genes.
|
9395242 |
1997 |